Brainsway Ltd
$ 15.50
-0.96%
07 Aug - close price
- Market Cap 628,054,000 USD
- Current Price $ 15.50
- High / Low $ 16.04 / 15.37
- Stock P/E 68.04
- Book Value 1.99
- EPS 0.23
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.03 %
- ROE 0.13 %
- 52 Week High 17.35
- 52 Week Low 5.88
About
Brainsway Ltd., a commercial-stage medical device company, focuses on the development and sale of non-invasive neuromodulation products in Israel and internationally. The company is headquartered in Jerusalem, Israel.
Analyst Target Price
$17.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-11 | 2025-11-11 | 2025-08-13 | 2025-05-13 | 2025-03-11 | 2024-11-12 | 2024-08-06 | 2024-05-08 | 2024-03-06 | 2023-11-15 | 2023-08-09 |
| Reported EPS | 0.06 | 0.0638 | 0.02 | 0.03 | 0.01 | 0.04 | 0.01 | 0.01 | 0.0067 | 0.0076 | -0.02 | -0.02 |
| Estimated EPS | 0.05 | 0.0456 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.04 |
| Surprise | 0.01 | 0.0182 | 0 | 0.01 | 0 | 0.02 | 0 | 0.02 | 0.0167 | 0.0176 | 0 | 0.02 |
| Surprise Percentage | 20% | 39.9123% | 0% | 50% | 0% | 100% | 0% | 200% | 167% | 176% | 0% | 50% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BWAY
2026-08-05 19:43:14
Renaissance Technologies LLC significantly increased its stake in Brainsway Ltd. Sponsored ADR (BWAY) during the first quarter by purchasing an additional 241,560 shares, bringing its total holdings to 518,420 shares valued at approximately $6.89 million. Other institutional investors also expanded their positions, contributing to 30.11% institutional ownership. Analysts maintain a "Buy" rating for Brainsway, with an average price target of $15.67, following strong quarterly results that surpassed revenue and EPS expectations.
2026-08-05 12:43:14
Brainsway (NASDAQ:BWAY) is projected to release its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts anticipate earnings of $0.10 per share and revenues of $16.54 million, with the earnings call scheduled for August 13th. The company surpassed expectations in the previous quarter, reporting $0.12 EPS against a $0.05 consensus.
2026-08-04 13:41:30
The article analyzes Brainsway Ltd. (NASDAQ: BWAY) using AI models, identifying a neutral near-term sentiment with resistance being tested. It presents three trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, noting an exceptional 78.8:1 risk-reward short setup.
2026-08-02 05:39:15
Wall Street Zen upgraded Brainsway (NASDAQ:BWAY) from a "hold" to a "buy" rating, reflecting a generally positive sentiment among analysts, with a consensus "Buy" rating and an average price target of $15.67. The company recently surpassed earnings expectations, reporting $0.12 EPS against a $0.05 consensus, and institutional investors hold a significant portion of its stock. Several other analysts have also issued "buy" ratings for Brainsway.
2026-07-31 08:40:50
TradingKey's stock analysis of Brainsway Ltd (BWAY) indicates strong fundamentals and high growth potential, with revenue increasing by an average of 64.31% over the past three years. The company is considered fairly valued and has a high institutional ownership, with multiple analysts rating it as a "Strong Buy" and a target price of $17.67. Despite an average stock market performance, the stock is trading sideways, making it suitable for range-bound swing trading.
2026-07-30 08:11:39
BrainsWay Ltd. will report its second quarter 2026 financial results and operational highlights on Wednesday, August 12, 2026, before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide a business update, and a separate webcast in Hebrew on August 13, 2026. BrainsWay is a leader in noninvasive neurostimulation with three FDA-cleared indications for its Deep TMS™ technology.
